Literature DB >> 16024663

Structural basis for competition between drug binding and Kvbeta 1.3 accessory subunit-induced N-type inactivation of Kv1.5 channels.

Niels Decher1, Pradeep Kumar, Teresa Gonzalez, Vijay Renigunta, Michael C Sanguinetti.   

Abstract

Kvbeta subunits are accessory proteins that modify gating of Kv1 channels. Kvbeta1.3 subunits bind to the N termini of Kv1.5 alpha-subunits and induce fast N-type inactivation, slow the rate of deactivation, and alter the voltage dependence and kinetics of channel activation. The N terminus of a Kvbeta subunit and quaternary ammonium compounds bind to the inner pore of Kv1 channels; however, it is unknown to what extent the pore binding sites for drugs and Kvbeta subunits overlap. Here, we used site-directed Ala mutagenesis to scan residues of the Kv1.5 pore to define the binding site for Kvbeta1.3 subunits. Individual mutations of five residues in the S6 domain (Val505, Ile508, Leu510, Val512, and Val516) greatly retarded or prevented Kvbeta1.3 induced inactivation, and reduced effects on Kv1.5 deactivation. Mutation of Thr479 and Thr480 enhanced Kvbeta1.3-induced N-type inactivation. None of the Ala mutations prevented the Kvbeta1.3-induced negative shifts in the voltage dependence of activation or slow C-type inactivation, suggesting that these gating effects are mediated by an interaction other than the one for N-type inactivation. Thr479, Thr480, Val505, Ile508, and Val512, of Kv1.5 channels are also important interaction sites for the anthranilic acid S0100176 (N-benzyl-N-pyridin-3-ylmethyl-2-(toluene-4-sulfonylamino)-benzamide hydrochloride). Leu510 and V516A prevented Kvbeta1.3-induced inactivation but did not alter drug block. Block of Kv1.5 by S0100176 was reduced and voltage-dependent in the presence of Kvbeta1.3 but not in the presence of an N-truncated form of the Kvbeta subunit. Thus, residues in the pore of Kv1.5 required for N-type inactivation overlap with but are not identical to the drug binding site.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024663     DOI: 10.1124/mol.105.011668

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1.

Authors:  Tao Yang; Brian F McBride; Brenda F Leake; Richard B Kim; Dan M Roden
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Modification of K+ channel-drug interactions by ancillary subunits.

Authors:  Glenna C L Bett; Randall L Rasmusson
Journal:  J Physiol       Date:  2007-12-20       Impact factor: 5.182

3.  Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state--docking and computer simulations of a homology model.

Authors:  Martin Andér; Victor B Luzhkov; Johan Aqvist
Journal:  Biophys J       Date:  2007-09-28       Impact factor: 4.033

4.  Structural determinants of Kvbeta1.3-induced channel inactivation: a hairpin modulated by PIP2.

Authors:  Niels Decher; Teresa Gonzalez; Anne Kathrin Streit; Frank B Sachse; Vijay Renigunta; Malle Soom; Stefan H Heinemann; Jürgen Daut; Michael C Sanguinetti
Journal:  EMBO J       Date:  2008-11-06       Impact factor: 11.598

5.  Regulation of human cardiac Kv1.5 channels by extracellular acidification.

Authors:  Shuang Wang; Wei-Guang Ding; Jia-Yu Bai; Futoshi Toyoda; Min-Jie Wei; Hiroshi Matsuura
Journal:  Pflugers Arch       Date:  2016-10-28       Impact factor: 3.657

Review 6.  Pharmacogenomics of cardiovascular complications in diabetes and obesity.

Authors:  Kalyan Chapalamadugu; Siva K Panguluri; Aimon Miranda; Kevin B Sneed; Srinivas M Tipparaju
Journal:  Recent Pat Biotechnol       Date:  2014

7.  RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels.

Authors:  Niels Decher; Anne K Streit; Markus Rapedius; Michael F Netter; Stefanie Marzian; Petra Ehling; Günter Schlichthörl; Tobias Craan; Vijay Renigunta; Annemarie Köhler; Richard C Dodel; Ricardo A Navarro-Polanco; Regina Preisig-Müller; Gerhard Klebe; Thomas Budde; Thomas Baukrowitz; Jürgen Daut
Journal:  EMBO J       Date:  2010-05-11       Impact factor: 11.598

8.  Protein kinase C (PKC) activity regulates functional effects of Kvβ1.3 subunit on KV1.5 channels: identification of a cardiac Kv1.5 channelosome.

Authors:  Miren David; Álvaro Macías; Cristina Moreno; Ángela Prieto; Ramón Martínez-Mármol; Rubén Vicente; Teresa González; Antonio Felipe; Michael M Tamkun; Carmen Valenzuela
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

9.  A highly conserved alanine in the S6 domain of the hERG1 K+ channel is required for normal gating.

Authors:  Scott Brown; David P Sonntag; Michael C Sanguinetti
Journal:  Cell Physiol Biochem       Date:  2008-12-09

10.  PKC inhibition results in a Kv 1.5 + Kv β1.3 pharmacology closer to Kv 1.5 channels.

Authors:  A Macías; A de la Cruz; A Prieto; D A Peraza; M M Tamkun; T González; C Valenzuela
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.